Meet our Director of Rheumatology
Meet Anne C. Bay-Jensen, Director of Rheumatology at Nordic Bioscience. She started working here in 2008, and just celebrated her 10-year anniversary 1 March 2018! Anne is the daily leader of 20 scientists and technicians. Her main-focus area is development, test and validation of biomarkers for translational science, drug development and personalized medicine.
Meet our Director of Fibrosis
Meet Diana Julie Leeming, Director of Fibrosis, and daily manager for 15 scientists and technicians developing the next generation of biomarkers at Nordic Bioscience. Diana has been working 14 years with Nordic Bioscience, 7 years with research in osteoporosis and now in her 8th year in fibrosis.
15 January, 2018
Last week the Nordic Bioscience Fibrosis team attended this years NASH-TAG conference in Park City, Utah. We had an oral presentation entitled "PRO-C3 In Combination With Clinical Parameters Is Associated With Severity of Histological Features Of Non-Alcoholic Steatohepatitis And Fibrosis".
This week our dedicated Cancer team will be present at the ASCO-GI conference in San Francisco. They have two poster presentations: "Serological Assessment Of Type XVI Collagen In Patients With Colorectal Cancer And Ulcerative Colitis" and "Effect Of MMP-13 Degraded SPARC On Type I Collagen And Its Biomarker Potential In Colorectal Cancer".
CE marking of PRO-C3
12 December, 2017
Nordic Bioscience is proud to announce the CE marking of the PRO-C3 assay. This is part of the large regulatory efforts undertaken to support biomarker use in clinical research and beyond. The marking signifies that the measurement of PRO-C3 is of extraordinarily high quality and controlled in appropriate manners. Measurement of PRO-C3 is a measurement of active fibroblasts producing type III collagen, and may be used in different important settings to support fibrosis research.
Nature paper published
11 December, 2017
There are good and bad collagens. We just published in the Nature Research journal, Scientific Reports, that the pro-peptide of type VI collagen (PRO-C6) which contains the bio-active fragment endotrophin, is a bad collagen fragment. We show that urinary levels of PRO-C6 are able to predict disease progression in patients with chronic kidney disease, independent of conventional risk factors. These results show that biomarkers of structural changes in the extracellular matrix may prove to be powerful tools in risk stratification.
LITMUS press release
24 November, 2017
We love the extracellular matrix (ECM) and our neo-epitope biomarkers aid in developing faster, better and cheaper targeted treatments. Therefore, we are also very proud to be part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project with the goal of developing, validating and qualifying better biomarkers for testing NAFLD. LITMUS will include 47 international research partners and has funding of €34 million. The LITMUS kick off meeting will take place in Newcastle, November 28-29, 2017.
The EU funded EPoS project
22 November, 2017
Nordic Bioscience is truly invested in developing biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD) and are therefore proud to be a part of the EU funded EPoS (EPoS: Elucidating Pathways of Steatohepatitis). The overall objective of the EPoS project is to develop a global understanding of how host and environmental factors interact at the cellular, organ and organism level to promote the development of NAFLD and, importantly, the progression to non-alcoholic steatohepatitis (NASH) and end-stage liver disease; and so provide a clear path for integrating these datasets to inform cost effective diagnosis, prevention and treatment strategies in Europe.
Merck KGaA and Nordic Bioscience in osteoarthritis breakthrough
November 4, 2017
Today, at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (ACR/AHRP), we announced the results of the two-year primary analysis of FORWARD - a five-year, multicenter Phase II study of sprifermin in patients with knee OA, conducted by Nordic Bioscience and Merck.
ECM Workshop - COPENHAGEN 18 - 19 APRIL 2018
Nordic Bioscience is delighted to invite you to our first ECM Workshop. The ECM (extra-cellular matrix) is receiving increased attention as a source of biomarkers for fibrotic, cancer and rheumatic disorders, but also as a source of drug targets. The ECM is controlling cell fate and function and the biology and understanding of the ECM and how to quantify it, is a hot topic. Our research group has over 350 publications on the ECM and biomarkers and we would like to encourage knowledge-sharing and research on ECM biology.
Lilly Announces Strategic Collaboration with KeyBioscience AG
8 June, 2017
Lilly Announces Strategic Collaboration with KeyBioscience AG
Companies to Collaborate on Developing New Class of Diabetes Treatments
The collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089 and KBP-056. KeyBioscience has initiated Phase 2 development with KBP-042. Other assets included in the collaboration, engineered for differences in effect or potency, range from Phase 1 to pre-clinical.
EULAR Conference 2017
7 June, 2017
The Nordic Bioscience Science Team will be at EULAR in Madrid from June 14-17. We are proud to have 12 accepted abstracts this year and together with good collaborators we will display the newest biomarker data within SSc, RA, PsA, AS and OA. Please reach out to Klaus Meyer Møller (firstname.lastname@example.org) to set up a meeting with the team or stop by one of our posters at the conference.
ASCO Annual Meeting 2017
4 June, 2017
Today the Nordic Bioscience group is presenting the poster "EXTRACELLULAR MATRIX (ECM) PROTEIN FRAGMENTS IN SERUM AND OUTCOMES IN TWO METASTATIC BREAST CANCER COHORTS" at ASCO Annual Meeting 2017 in Chicago. We show that extracellular matrix (ECM) protein fragments in serum is predictive of outcome in two metastatic breast cancer cohorts. Please reach out to Louise Brink Thomsen (email@example.com) to set up a meeting with the team or stop by our poster at the conference.
OARSI Conference 2017
7 May, 2017
With a total of 10 accepted abstracts we are proud to be at the OARSI meeting this week. Come and learn how to utilize biomarkers in pharmaceutical research and development at our 2 oral presentations and 8 posters throughout the conference. We will be happy to discuss biomarker strategies for evaluating joint health from early preclinical research to late stage clinical Development.
6 October, 2016
NORDIC BIOSCIENCE JOINS NON-PROFIT CONSORTIUM TO CURE HEARING LOSS. As a part of our engagement in innovative science and unmet medical needs, the Nordic Bioscience Clinical Development division has entered into a non-profit EU-funded project, REGAIN, with a promising medical treatment for sensorineural hearing loss; the most common type of hearing loss. The REGAIN project aims to develop and clinically test a new medical treatment of hearing loss caused by the loss of sensory hair cells in the inner ear, in two early clinical trials in Europe. The trials will be managed by the trial expert team at Nordic Bioscience.
17 April, 2017
Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology
24 March, 2017
We are very proud to be part of the LITMUS consortium, (LITMUS: Liver Investigation - Testing Marker Utility in Steatohepatitis) which was just awarded a prestigious IMI grant. The overarching aim of LITMUS is to develop, validate and advance towards regulatory qualification biomarkers that are able to diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. The ultimate goal is to establish a defined panel of biomarkers that, singly or in combination, enables detection and monitoring of disease progression/regression from NAFL through NASH to fibrosis and cirrhosis.
26 August, 2016
Together with Elsevier science, Nordic Bioscience have taken the time to condense all our collagen, elastin and laminin knowledge into one book. We are very proud of that the book focuses on biology and biomarkers of ECM and provides particular insights into collagens, laminins and elastin. We hope this will advance the interest and research of biomarkers in the ECM field associated with pathologies such as cancer, fibrosis and rheumatologic disorders.
An Intelligent Approach to Clinical Trial Monitoring
Many pharmaceutical companies are excited by Risk-Based Monitoring but are uncertain about how to implement such an initiative.
Nordic Bioscience has pioneered Risk-Based Monitoring since 2011 and our mission is to provide the industry with credible data that supports a change in the monitoring approach.
Recently, we published a review in the European Journal of Clinical Pharmacology that supports risk-based monitoring and concludes that reduced source data verification combined with a centralized, risk-based approach may be the solution to reduce monitoring costs while improving data quality.
Novel Biomarker Research
Nordic Bioscience to participate in EU funded ALD research project GALAXY
16 December, 2015
For the next 6 years, Nordic Bioscience will be part of the EU funded Alcoholic Liver Disease (ALD) research project GALAXY, which has a total budget of DKR 47 million. The aim is to find an easy and effective way to identify the people who do not know that they have the disease. Nordic Bioscience’s contribution is evaluation of our Protein Fingerprint biomarkers for early diagnosis, treatment monitoring, selection of patients for treatment and predictive for drug treatment response in patients with alcoholic liver disease.
Nordic Bioscience’s central and specialized laboratory services continue to grow
EU funded OA research project APPROACH
23 September, 2015
For the next 6 years Nordic Bioscience will play a significant role in the EU funded osteoarthritis (OA) research project APPROACH, which has a total budget of EUR 15 million. The aim is to identify the patients most likely to respond to a given treatment using a validated biomarker drug development tool box for OA. Nordic Bioscience’s contribution is application of our validated proprietary Protein Fingerprint biomarkers, our FDA certified laboratory to ensure high quality and reproducibility of measurements, and regulatory approval process expertise.
Successful completion of phase I study
19 August, 2015
Together with our subsidiary KeyBioscience AG, we are proud to announce the successful completion of our phase I study with our novel Dual Amylin and Calcitonin Receptor Agonist (DACRA) that we currently are developing for type 2 diabetes, obesity and NASH. The DACRA KBP-042 is an insulin sensitizer which causes a significant weight reduction. The study confirmed tolerability of the molecule and more importantly indicated a substantial potential for treatment efficacy in the target population.